Compile Data Set for Download or QSAR
Report error Found 2444 of affinity data for UniProtKB/TrEMBL: P06870
TargetKallikrein-1(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM619925(US20230295157, Example 249 | N-(4-(2-((3S,8a*R)-7-...)
Affinity DataIC50: 0.400nMAssay Description:A fluorescence intensity (FLINT) based assay was used to monitor inhibition of human plasma kallikrein. The peptide substrate, Z-Gly-Pro-Arg-AMC (Pur...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
Go to US Patent

TargetKallikrein-1(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM619946(US20230295157, Example 270)
Affinity DataIC50: 0.400nMAssay Description:A fluorescence intensity (FLINT) based assay was used to monitor inhibition of human plasma kallikrein. The peptide substrate, Z-Gly-Pro-Arg-AMC (Pur...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
Go to US Patent

TargetKallikrein-1(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM620044(US20230295157, Example 369 | N-(2-(2-((3S,8aR)-7-(...)
Affinity DataIC50: 0.5nMAssay Description:A fluorescence intensity (FLINT) based assay was used to monitor inhibition of human plasma kallikrein. The peptide substrate, Z-Gly-Pro-Arg-AMC (Pur...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
Go to US Patent

TargetKallikrein-1(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM619910(US20230295157, Example 234)
Affinity DataIC50: 0.600nMAssay Description:A fluorescence intensity (FLINT) based assay was used to monitor inhibition of human plasma kallikrein. The peptide substrate, Z-Gly-Pro-Arg-AMC (Pur...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
Go to US Patent

TargetKallikrein-1(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM619988(US20230295157, Example 312 | 5-(2-((3S)-7-(3-Chlor...)
Affinity DataIC50: 0.600nMAssay Description:A fluorescence intensity (FLINT) based assay was used to monitor inhibition of human plasma kallikrein. The peptide substrate, Z-Gly-Pro-Arg-AMC (Pur...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
Go to US Patent

TargetKallikrein-1(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM619989(US20230295157, Example 313 | (3S)-3-(5-(3-Amino-1H...)
Affinity DataIC50: 0.600nMAssay Description:A fluorescence intensity (FLINT) based assay was used to monitor inhibition of human plasma kallikrein. The peptide substrate, Z-Gly-Pro-Arg-AMC (Pur...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
Go to US Patent

TargetKallikrein-1(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM345078(US9783530, 23 | 2-(1-((4-Carboxyphenyl)amino)-1-ox...)
Affinity DataIC50: 0.700nMAssay Description:Kallikrein determinations were made in 50 mM HEPES buffer at pH 7.4 containing 150 mM NaCl, 5 mM CaCl2, and 0.1% PEG 8000 (polyethylene glycol; Fishe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2019
Entry Details
Go to US Patent

TargetKallikrein-1(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM619894(US20230295157, Example 218 | 4-(5-Chloro-2-((3S)-7...)
Affinity DataIC50: 0.700nMAssay Description:A fluorescence intensity (FLINT) based assay was used to monitor inhibition of human plasma kallikrein. The peptide substrate, Z-Gly-Pro-Arg-AMC (Pur...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
Go to US Patent

TargetKallikrein-1(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM619914(US20230295157, Example 238 | 5-(2-((3*S,8aR)-7-(3-...)
Affinity DataIC50: 0.700nMAssay Description:A fluorescence intensity (FLINT) based assay was used to monitor inhibition of human plasma kallikrein. The peptide substrate, Z-Gly-Pro-Arg-AMC (Pur...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
Go to US Patent

TargetKallikrein-1(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM619926(US20230295157, Example 250 | N-(4-(24(3S,8aS*)-7-(...)
Affinity DataIC50: 0.700nMAssay Description:A fluorescence intensity (FLINT) based assay was used to monitor inhibition of human plasma kallikrein. The peptide substrate, Z-Gly-Pro-Arg-AMC (Pur...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
Go to US Patent

TargetKallikrein-1(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM619933(US20230295157, Example 257 | N-[2-[2-[(3S,8aR)-7-[...)
Affinity DataIC50: 0.700nMAssay Description:A fluorescence intensity (FLINT) based assay was used to monitor inhibition of human plasma kallikrein. The peptide substrate, Z-Gly-Pro-Arg-AMC (Pur...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
Go to US Patent

TargetKallikrein-1(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM619937(US20230295157, Example 261)
Affinity DataIC50: 0.700nMAssay Description:A fluorescence intensity (FLINT) based assay was used to monitor inhibition of human plasma kallikrein. The peptide substrate, Z-Gly-Pro-Arg-AMC (Pur...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
Go to US Patent

TargetKallikrein-1(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM619968(US20230295157, Example 292 | 5-(2-((3S,8aS)-7-(3-C...)
Affinity DataIC50: 0.700nMAssay Description:A fluorescence intensity (FLINT) based assay was used to monitor inhibition of human plasma kallikrein. The peptide substrate, Z-Gly-Pro-Arg-AMC (Pur...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
Go to US Patent

TargetKallikrein-1(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM619983(US20230295157, Example 307 | N-(2-(2-((3S,8aR)-7-(...)
Affinity DataIC50: 0.700nMAssay Description:A fluorescence intensity (FLINT) based assay was used to monitor inhibition of human plasma kallikrein. The peptide substrate, Z-Gly-Pro-Arg-AMC (Pur...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
Go to US Patent

TargetKallikrein-1(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM619987(US20230295157, Example 311 | 6-(2-((3S)-7-(3-Chlor...)
Affinity DataIC50: 0.700nMAssay Description:A fluorescence intensity (FLINT) based assay was used to monitor inhibition of human plasma kallikrein. The peptide substrate, Z-Gly-Pro-Arg-AMC (Pur...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
Go to US Patent

TargetKallikrein-1(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM619887(US20230295157, Example 211 | 5-(5-Chloro-2-((3S,8a...)
Affinity DataIC50: 0.800nMAssay Description:A fluorescence intensity (FLINT) based assay was used to monitor inhibition of human plasma kallikrein. The peptide substrate, Z-Gly-Pro-Arg-AMC (Pur...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
Go to US Patent

TargetKallikrein-1(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM619934(US20230295157, Example 258 | (3S)-7-[3-Chloro-2-fl...)
Affinity DataIC50: 0.800nMAssay Description:A fluorescence intensity (FLINT) based assay was used to monitor inhibition of human plasma kallikrein. The peptide substrate, Z-Gly-Pro-Arg-AMC (Pur...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
Go to US Patent

TargetKallikrein-1(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM619957(US20230295157, Example 281 | 6-(2-((3S,8aR)-7-(3-C...)
Affinity DataIC50: 0.800nMAssay Description:A fluorescence intensity (FLINT) based assay was used to monitor inhibition of human plasma kallikrein. The peptide substrate, Z-Gly-Pro-Arg-AMC (Pur...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
Go to US Patent

TargetKallikrein-1(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM619947(US20230295157, Example 271)
Affinity DataIC50: 0.900nMAssay Description:A fluorescence intensity (FLINT) based assay was used to monitor inhibition of human plasma kallikrein. The peptide substrate, Z-Gly-Pro-Arg-AMC (Pur...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
Go to US Patent

TargetKallikrein-1(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM620045(US20230295157, Example 370 | N-(4-(2-((3S)-7-(3-ch...)
Affinity DataIC50: 0.900nMAssay Description:A fluorescence intensity (FLINT) based assay was used to monitor inhibition of human plasma kallikrein. The peptide substrate, Z-Gly-Pro-Arg-AMC (Pur...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
Go to US Patent

TargetKallikrein-1(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM619828(US20230295157, Example 152 | 6-[2-[(3S,8a*R)-7-[3-...)
Affinity DataIC50: 1nMAssay Description:A fluorescence intensity (FLINT) based assay was used to monitor inhibition of human plasma kallikrein. The peptide substrate, Z-Gly-Pro-Arg-AMC (Pur...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
Go to US Patent

TargetKallikrein-1(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM619941(US20230295157, Example 265)
Affinity DataIC50: 1nMAssay Description:A fluorescence intensity (FLINT) based assay was used to monitor inhibition of human plasma kallikrein. The peptide substrate, Z-Gly-Pro-Arg-AMC (Pur...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
Go to US Patent

TargetKallikrein-1(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM619973(US20230295157, Example 297 | 6-(2-((3S)-7-(3-Chlor...)
Affinity DataIC50: 1nMAssay Description:A fluorescence intensity (FLINT) based assay was used to monitor inhibition of human plasma kallikrein. The peptide substrate, Z-Gly-Pro-Arg-AMC (Pur...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
Go to US Patent

TargetKallikrein-1(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM652564(US20240059691, Example 1303 | N5-((4-methyl-6-(8-m...)
Affinity DataIC50: 1nMAssay Description:In vitro inhibition of related proteases was determined using an (C50 assay based on standard literature methods (see e.g. Shori et al., Biochem. Pha...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
Go to US Patent

TargetKallikrein-1(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM652566(US20240059691, Example 1305 | (S*)-N5-((4-methyl-6...)
Affinity DataIC50: 1nMAssay Description:In vitro inhibition of related proteases was determined using an (C50 assay based on standard literature methods (see e.g. Shori et al., Biochem. Pha...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
Go to US Patent

TargetKallikrein-1(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM652569(US20240059691, Example 1309 | N5-((4-ethyl-6-(3-(t...)
Affinity DataIC50: 1nMAssay Description:In vitro inhibition of related proteases was determined using an (C50 assay based on standard literature methods (see e.g. Shori et al., Biochem. Pha...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
Go to US Patent

TargetKallikrein-1(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM652573(US20240059691, Example 1313 | 2-chloro-N-((4-methy...)
Affinity DataIC50: 1nMAssay Description:In vitro inhibition of related proteases was determined using an (C50 assay based on standard literature methods (see e.g. Shori et al., Biochem. Pha...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
Go to US Patent

TargetKallikrein-1(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM652764(US20240059691, Example 9005 | N5-((3-methyl-5-(3-(...)
Affinity DataIC50: 1nMAssay Description:In vitro inhibition of related proteases was determined using an (C50 assay based on standard literature methods (see e.g. Shori et al., Biochem. Pha...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
Go to US Patent

TargetKallikrein-1(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM619810(US20230295157, Example 134 | (3S,8aR)-7-(3-chloro-...)
Affinity DataIC50: 1.10nMAssay Description:A fluorescence intensity (FLINT) based assay was used to monitor inhibition of human plasma kallikrein. The peptide substrate, Z-Gly-Pro-Arg-AMC (Pur...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
Go to US Patent

TargetKallikrein-1(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM619854(US20230295157, Example 178 | (3R,8aR)-7-(3-chloro-...)
Affinity DataIC50: 1.10nMAssay Description:A fluorescence intensity (FLINT) based assay was used to monitor inhibition of human plasma kallikrein. The peptide substrate, Z-Gly-Pro-Arg-AMC (Pur...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
Go to US Patent

TargetKallikrein-1(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM619942(US20230295157, Example 266)
Affinity DataIC50: 1.10nMAssay Description:A fluorescence intensity (FLINT) based assay was used to monitor inhibition of human plasma kallikrein. The peptide substrate, Z-Gly-Pro-Arg-AMC (Pur...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
Go to US Patent

TargetKallikrein-1(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM619953(US20230295157, Example 277 | 6-(2-((3S,8aR)-7-(3-C...)
Affinity DataIC50: 1.10nMAssay Description:A fluorescence intensity (FLINT) based assay was used to monitor inhibition of human plasma kallikrein. The peptide substrate, Z-Gly-Pro-Arg-AMC (Pur...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
Go to US Patent

TargetKallikrein-1(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM619962(US20230295157, Example 286 | 5-(2-((3S,8aR)-7-(3-C...)
Affinity DataIC50: 1.10nMAssay Description:A fluorescence intensity (FLINT) based assay was used to monitor inhibition of human plasma kallikrein. The peptide substrate, Z-Gly-Pro-Arg-AMC (Pur...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
Go to US Patent

TargetKallikrein-1(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM345057(4-{[(2R)-2-{5-[5-chloro- 2-(1H-tetrazol-1- yl)phen...)
Affinity DataIC50: 1.20nMAssay Description:Kallikrein determinations were made in 50 mM HEPES buffer at pH 7.4 containing 150 mM NaCl, 5 mM CaCl2, and 0.1% PEG 8000 (polyethylene glycol; Fishe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2019
Entry Details
Go to US Patent

TargetKallikrein-1(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM619952(US20230295157, Example 276 | N-(2-(2-((3S)-7-(3-Ch...)
Affinity DataIC50: 1.20nMAssay Description:A fluorescence intensity (FLINT) based assay was used to monitor inhibition of human plasma kallikrein. The peptide substrate, Z-Gly-Pro-Arg-AMC (Pur...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
Go to US Patent

TargetKallikrein-1(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM619956(US20230295157, Example 280 | 6-(2-((3S,8aS)-7-(3-C...)
Affinity DataIC50: 1.20nMAssay Description:A fluorescence intensity (FLINT) based assay was used to monitor inhibition of human plasma kallikrein. The peptide substrate, Z-Gly-Pro-Arg-AMC (Pur...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
Go to US Patent

TargetKallikrein-1(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM620047(US20230295157, Example 372 | (3S,8aR)-3-(5-(2-amin...)
Affinity DataIC50: 1.20nMAssay Description:A fluorescence intensity (FLINT) based assay was used to monitor inhibition of human plasma kallikrein. The peptide substrate, Z-Gly-Pro-Arg-AMC (Pur...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
Go to US Patent

TargetKallikrein-1(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM619985(US20230295157, Example 309 | 6-(2-((3S)-7-(3-Chlor...)
Affinity DataIC50: 1.30nMAssay Description:A fluorescence intensity (FLINT) based assay was used to monitor inhibition of human plasma kallikrein. The peptide substrate, Z-Gly-Pro-Arg-AMC (Pur...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
Go to US Patent

TargetKallikrein-1(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM620005(US20230295157, Example 329 | N-(2-(2-((3S)-7-(3-Ch...)
Affinity DataIC50: 1.30nMAssay Description:A fluorescence intensity (FLINT) based assay was used to monitor inhibition of human plasma kallikrein. The peptide substrate, Z-Gly-Pro-Arg-AMC (Pur...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
Go to US Patent

TargetKallikrein-1(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM620017(US20230295157, Example 341 | Methyl (4-(2-((3S,8aR...)
Affinity DataIC50: 1.30nMAssay Description:A fluorescence intensity (FLINT) based assay was used to monitor inhibition of human plasma kallikrein. The peptide substrate, Z-Gly-Pro-Arg-AMC (Pur...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
Go to US Patent

TargetKallikrein-1(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM620063(US20230295157, Example 390 | (3S,8aR)-7-(3-chloro-...)
Affinity DataIC50: 1.30nMAssay Description:A fluorescence intensity (FLINT) based assay was used to monitor inhibition of human plasma kallikrein. The peptide substrate, Z-Gly-Pro-Arg-AMC (Pur...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
Go to US Patent

TargetKallikrein-1(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM619855(US20230295157, Example 179 | (3R,8aR)-7-(3-chloro-...)
Affinity DataIC50: 1.40nMAssay Description:A fluorescence intensity (FLINT) based assay was used to monitor inhibition of human plasma kallikrein. The peptide substrate, Z-Gly-Pro-Arg-AMC (Pur...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
Go to US Patent

TargetKallikrein-1(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM620030(US20230295157, Example 355 | Methyl (4-(2-((3S)-7-...)
Affinity DataIC50: 1.40nMAssay Description:A fluorescence intensity (FLINT) based assay was used to monitor inhibition of human plasma kallikrein. The peptide substrate, Z-Gly-Pro-Arg-AMC (Pur...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
Go to US Patent

TargetKallikrein-1(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM619878(US20230295157, Example 202 | 5-(5-Chloro-2-((3S,8a...)
Affinity DataIC50: 1.5nMAssay Description:A fluorescence intensity (FLINT) based assay was used to monitor inhibition of human plasma kallikrein. The peptide substrate, Z-Gly-Pro-Arg-AMC (Pur...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
Go to US Patent

TargetKallikrein-1(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM619913(US20230295157, Example 237 | 3-(2-((3S,8aR)-7-(3-C...)
Affinity DataIC50: 1.5nMAssay Description:A fluorescence intensity (FLINT) based assay was used to monitor inhibition of human plasma kallikrein. The peptide substrate, Z-Gly-Pro-Arg-AMC (Pur...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
Go to US Patent

TargetKallikrein-1(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM619924(US20230295157, Example 248 | N-[2-[2-[(3S)-7-[3-Ch...)
Affinity DataIC50: 1.5nMAssay Description:A fluorescence intensity (FLINT) based assay was used to monitor inhibition of human plasma kallikrein. The peptide substrate, Z-Gly-Pro-Arg-AMC (Pur...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
Go to US Patent

TargetKallikrein-1(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM619955(US20230295157, Example 279 | N-(2-(2-((3S)-7-(3-Ch...)
Affinity DataIC50: 1.5nMAssay Description:A fluorescence intensity (FLINT) based assay was used to monitor inhibition of human plasma kallikrein. The peptide substrate, Z-Gly-Pro-Arg-AMC (Pur...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
Go to US Patent

TargetKallikrein-1(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM620049(US20230295157, Example 374 | 7-(3-chloro-2-fluoro-...)
Affinity DataIC50: 1.5nMAssay Description:A fluorescence intensity (FLINT) based assay was used to monitor inhibition of human plasma kallikrein. The peptide substrate, Z-Gly-Pro-Arg-AMC (Pur...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
Go to US Patent

TargetKallikrein-1(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM619764(US20230295157, Example 87)
Affinity DataIC50: 1.60nMAssay Description:A fluorescence intensity (FLINT) based assay was used to monitor inhibition of human plasma kallikrein. The peptide substrate, Z-Gly-Pro-Arg-AMC (Pur...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
Go to US Patent

TargetKallikrein-1(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM619794(US20230295157, Example 118 | 6-(24(3*S,8a*R)-7-(3-...)
Affinity DataIC50: 1.70nMAssay Description:A fluorescence intensity (FLINT) based assay was used to monitor inhibition of human plasma kallikrein. The peptide substrate, Z-Gly-Pro-Arg-AMC (Pur...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
Go to US Patent

Displayed 1 to 50 (of 2444 total ) | Next | Last >>
Jump to: